BXPH.F Stock Overview
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.32 |
| 52 Week High | AU$0.50 |
| 52 Week Low | AU$0.0085 |
| Beta | 1.93 |
| 1 Month Change | 45.45% |
| 3 Month Change | 416.96% |
| 1 Year Change | 166.67% |
| 3 Year Change | 702.01% |
| 5 Year Change | 300.00% |
| Change since IPO | 60.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.7% | 1.6% | -2.2% |
| 1Y | 166.7% | 9.7% | 23.9% |
Return vs Industry: BXPH.F exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: BXPH.F exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| BXPH.F volatility | |
|---|---|
| BXPH.F Average Weekly Movement | 160.3% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BXPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BXPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BXPH.F fundamental statistics | |
|---|---|
| Market cap | US$431.62m |
| Earnings (TTM) | -US$8.67m |
| Revenue (TTM) | US$1.29m |
333.7x
P/S Ratio-49.8x
P/E RatioIs BXPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXPH.F income statement (TTM) | |
|---|---|
| Revenue | AU$2.07m |
| Cost of Revenue | AU$3.65m |
| Gross Profit | -AU$1.58m |
| Other Expenses | AU$12.29m |
| Earnings | -AU$13.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | -76.48% |
| Net Profit Margin | -670.20% |
| Debt/Equity Ratio | 0% |
How did BXPH.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:56 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |